Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood. 2012;120(24):4684-4691.

On page 4686 in the 6 December 2012 issue, there are errors in the information described for follow-up studies. In the “Targeting SYK” section, in the seventh sentence of the first paragraph under the heading, “Clinical experience,” “B-cell malignancies” should have been “CLL” and “phase 3” should have been “phase 2.” The sentence stated, “So far, no follow-up studies of fostamatinib in B-cell malignancies have been initiated, although a recently completed randomized phase 3 study in rheumatoid arthritis showed significant activity and good tolerability of the drug.⁴⁷” The sentence should have read, “So far no follow-up studies of fostamatinib in CLL have been initiated, although a recently completed randomized phase 2 study in rheumatoid arthritis showed significant activity and good tolerability of the drug.⁴⁷” Indeed, in January 2012, AstraZeneca opened a study titled, “Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),” ClinicalTrials.gov Identifier: NCT01499303 (http://clinicaltrials.gov/ct2/show/NCT01499303?term=fostamatinib+dlbcl&rank=1).